Radiant Research/CRA Enrolls More Than 8,000 Subjects
Radiant Research/CRA has completed enrollment for the Dynavax Technologies Phase III clinical trial
Radiant Research/Clinical Research Advantage (Radiant/CRA), a wholly owned clinical trial site management organization, has completed enrollment for the Dynavax Technologies Phase III clinical trial of HEPLISAV-B™, an investigational adult hepatitis B vaccine. Radiant/CRA was awarded 100 percent of the study and 40 of its sites are conducting the trial, which has randomized over 8,250 adults, including over 1,100 diabetic subjects. The sites completed the enrollment three months ahead of schedule without the use of an outside recruiting company.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025